TY - JOUR
TI - Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia
AU - Papadopoulou, V.
AU - Kontandreopoulou, E.
AU - Panayiotidis, P.
AU - Roumelioti, M.
AU - Angelopoulou, M.
AU - Kyriazopoulou, L.
AU - Diamantopoulos, P.T.
AU - Vaiopoulos, G.
AU - Variami, E.
AU - Kotsianidis, I.
AU - Athina Viniou, N.
JO - Clinical Lymphoma Myeloma and Leukemia
PY - 2016
VL - 57
TODO - 5
SP - 1182-1188
PB - Taylor and Francis Ltd.
SN - null
TODO - 10.3109/10428194.2015.1090573
TODO - BCR ABL protein;  protein tyrosine phosphatase SHP 1;  BCR ABL protein;  protein kinase inhibitor;  protein tyrosine phosphatase SHP 1, adult;  aged;  amino acid sequence;  Article;  autoregulation;  cancer prognosis;  chronic myeloid leukemia;  clinical article;  comparative study;  controlled study;  exon;  female;  gene expression;  gene frequency;  human;  male;  mutational analysis;  pathogenesis;  priority journal;  protein binding;  protein expression;  real time polymerase chain reaction;  reverse transcription;  case control study;  dna mutational analysis;  gene expression regulation;  genetics;  Leukemia, Myelogenous, Chronic, BCR-ABL Positive;  middle aged;  mortality;  mutation;  myeloid leukemia;  prognosis;  single nucleotide polymorphism;  treatment outcome;  very elderly;  young adult, Adult;  Aged;  Aged, 80 and over;  Case-Control Studies;  DNA Mutational Analysis;  Female;  Fusion Proteins, bcr-abl;  Gene Expression Regulation, Leukemic;  Humans;  Leukemia, Myelogenous, Chronic, BCR-ABL Positive;  Leukemia, Myeloid, Chronic-Phase;  Male;  Middle Aged;  Mutation;  Polymorphism, Single Nucleotide;  Prognosis;  Protein Kinase Inhibitors;  Protein Tyrosine Phosphatase, Non-Receptor Type 6;  Treatment Outcome;  Young Adult
TODO - The protein tyrosine phosphatase SHP-1 dephosphorylates BCR-ABL1, thereby serving as a potential control mechanism of BCR-ABL1 kinase activity. Pathways regulating SHP-1 expression, which could be exploited in the therapeutics of TKI-resistant chronic myeloid leukemia (CML), remain unknown. Moreover, the questions of whether there is any kind of SHP-1 deregulation in CML, contributing to disease initiation or evolution, as well as the question of prognostic significance of SHP-1, have not been definitively answered. This study shows moderately lower SHP-1 mRNA expression in chronic phase CML patients in comparison to healthy individuals and no change in SHP-1 mRNA levels after successful TKI treatment. Mutational analysis of the aminoterminal and phosphatase domains of SHP-1 in patients did not reveal genetic lesions. This study also found no correlation of SHP-1 expression at diagnosis with response to treatment, although a trend for lower SHP-1 expression was noted in the very small non-responders group of the 3-month therapeutic milestone. © 2015 Taylor and Francis.
ER -